Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | CHRNA7 | P36544 | 6/20 | 0.43 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.43 |
| ▸ | HTR3B | O95264 | 4/20 | 0.43 |
| ▸ | HTR3A | P46098 | 4/20 | 0.43 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.43 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.43 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5107232 | 0.83 | KCNH2 (0.50) | KCNH2CHRNA7TLR9TLR8TLR7 | |
| SCHEMBL5114288 | 0.81 | KCNH2 (0.79) | KCNH2CHRNA7TLR9TLR8TLR7 | |
| SCHEMBL5110768 | 0.78 | KCNH2 (0.57) | KCNH2 | |
| SCHEMBL5112511 | 0.72 | KCNH2 (1.00) | KCNH2TLR9TLR8TLR7 | |
| SCHEMBL5113309 | 0.70 | KCNH2 (0.52) | KCNH2TLR7 | |
| SCHEMBL15441263 | 0.70 | HTR3A (0.71) | HTR3A | |
| SCHEMBL13733192 | 0.70 | HTR3A (0.71) | HTR3A | |
| SCHEMBL5114200 | 0.68 | KCNH2 (0.72) | KCNH2 | |
| SCHEMBL5109569 | 0.67 | KCNH2 (0.61) | KCNH2TLR9TLR8TLR7 | |
| SCHEMBL9718617 | 0.67 | KCNH2 (0.65) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080103170-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2008-05-01 | — | — | US | claimed |
| US-20080103170-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103170-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103170-A1 | Nicotinic Acetylcholine Receptor Ligands | CHRNG, CHRNE, CHRNA1 | KCNH2 501/4885CHRNA7 7/4885HTR3E 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.